UMB Bank n.a. Sells 4,137 Shares of Abbott Laboratories (NYSE:ABT)

UMB Bank n.a. decreased its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 256,392 shares of the healthcare product maker's stock after selling 4,137 shares during the quarter. UMB Bank n.a.'s holdings in Abbott Laboratories were worth $29,000,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. State Street Corp boosted its stake in Abbott Laboratories by 3.1% during the 3rd quarter. State Street Corp now owns 76,720,429 shares of the healthcare product maker's stock valued at $8,746,896,000 after purchasing an additional 2,323,807 shares during the period. Geode Capital Management LLC lifted its position in Abbott Laboratories by 1.4% during the 3rd quarter. Geode Capital Management LLC now owns 34,903,198 shares of the healthcare product maker's stock worth $3,963,974,000 after buying an additional 488,764 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Abbott Laboratories by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 25,810,977 shares of the healthcare product maker's stock valued at $2,942,709,000 after buying an additional 280,441 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Abbott Laboratories by 25.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 13,319,347 shares of the healthcare product maker's stock valued at $1,518,539,000 after buying an additional 2,711,586 shares during the period. Finally, Fisher Asset Management LLC grew its position in shares of Abbott Laboratories by 5.6% during the 3rd quarter. Fisher Asset Management LLC now owns 11,102,204 shares of the healthcare product maker's stock worth $1,265,762,000 after buying an additional 585,915 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ABT. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the company an "equal weight" rating in a research report on Thursday, October 17th. Raymond James reaffirmed a "buy" rating and issued a $129.00 target price (up previously from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Evercore ISI boosted their price target on Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research note on Thursday, January 2nd. UBS Group boosted their price target on Abbott Laboratories from $143.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, October 17th. Finally, Royal Bank of Canada boosted their price objective on Abbott Laboratories from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $131.57.

Abbott Laboratories Price Performance

Shares of NYSE ABT traded down $0.46 during mid-day trading on Monday, reaching $113.45. The company's stock had a trading volume of 6,443,213 shares, compared to its average volume of 4,199,178. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $121.64. The stock has a fifty day moving average of $114.93 and a two-hundred day moving average of $112.87. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The firm has a market capitalization of $196.78 billion, a PE ratio of 34.48, a P/E/G ratio of 2.40 and a beta of 0.73.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 annualized dividend and a yield of 2.08%. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.55. Abbott Laboratories's dividend payout ratio (DPR) is currently 66.87%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.